Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy
© 2024 Yin et al..
Radiation therapy (RT) is one of the most commonly used anticancer therapies. However, the landscape of cellular response to irradiation, especially to a single high-dose irradiation, remains largely unknown. In this study, we performed a whole-genome CRISPR loss-of-function screen and revealed temporal inherent and acquired responses to RT. Specifically, we found that loss of the IL1R1 pathway led to cellular resistance to RT. This is in part because of the involvement of radiation-induced IL1R1-dependent transcriptional regulation, which relies on the NF-κB pathway. Moreover, the mitochondrial anti-apoptotic pathway, particularly the BCL2L1 gene, is crucially important for cell survival after radiation. BCL2L1 inhibition combined with RT dramatically impeded tumor growth in several breast cancer cell lines and syngeneic models. Taken together, our results suggest that the combination of an apoptosis inhibitor such as a BCL2L1 inhibitor with RT may represent a promising anticancer strategy for solid cancers including breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Life science alliance - 7(2024), 4 vom: 05. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.02.2024 Date Revised 08.03.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.26508/lsa.202302353 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368057224 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368057224 | ||
| 003 | DE-627 | ||
| 005 | 20240309232231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26508/lsa.202302353 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM368057224 | ||
| 035 | |a (NLM)38316463 | ||
| 035 | |a (PII)e202302353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2024 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Yin et al. | ||
| 520 | |a Radiation therapy (RT) is one of the most commonly used anticancer therapies. However, the landscape of cellular response to irradiation, especially to a single high-dose irradiation, remains largely unknown. In this study, we performed a whole-genome CRISPR loss-of-function screen and revealed temporal inherent and acquired responses to RT. Specifically, we found that loss of the IL1R1 pathway led to cellular resistance to RT. This is in part because of the involvement of radiation-induced IL1R1-dependent transcriptional regulation, which relies on the NF-κB pathway. Moreover, the mitochondrial anti-apoptotic pathway, particularly the BCL2L1 gene, is crucially important for cell survival after radiation. BCL2L1 inhibition combined with RT dramatically impeded tumor growth in several breast cancer cell lines and syngeneic models. Taken together, our results suggest that the combination of an apoptosis inhibitor such as a BCL2L1 inhibitor with RT may represent a promising anticancer strategy for solid cancers including breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a bcl-X Protein |2 NLM | |
| 650 | 7 | |a BCL2L1 protein, human |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 700 | 1 | |a Hu, Xiaoding |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Guangsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Mengfan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, You |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Huimin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Siting |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Citu, Citu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zhongming |e verfasserin |4 aut | |
| 700 | 1 | |a Debeb, Bisrat G |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Junjie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life science alliance |d 2018 |g 7(2024), 4 vom: 05. März |w (DE-627)NLM286067536 |x 2575-1077 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:4 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26508/lsa.202302353 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 4 |b 05 |c 03 | ||